Comparative Analysis of Pharmacokinetic Properties of the FDA-Approved Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Drugs

Ankitha V, Sailakshmi Iyer

Abstract: Introduction: Ovarian, Fallopian tube, and peritoneal cancers are cancers that are commonly observed in post-menopausal women. In the general description, "ovarian cancer" is the term used in describing these cancers. Ovarian cancer is the 5th leading cause of cancer deaths in women with a 5-year survival rate. Ovarian cancer is commonly diagnosed in women aged 65 years or older. Early detection and appropriate treatment options can help in steadily decreasing the death rates. Materials and methods: The detailed study is performed by using online bioinformatics web tools such as NCI to retrieve the list of query drugs, PubChem to obtain the canonical smiles of the drugs, and Swiss ADME to compute the Absorption, Distribution, Metabolism, and Excretion properties of each drug candidate. Result: The study succeeded in identifying the best drug candidates among the list of FDA-approved (Food and Drug Administration) drugs in the treatment of ovarian, fallopian tube, and peritoneal cancers by analyzing various pharmacokinetic properties.

Keywords: Ovarian Cancer, NCI, PubChem, Swiss ADME

How to Cite?: Ankitha V, Sailakshmi Iyer, "Comparative Analysis of Pharmacokinetic Properties of the FDA-Approved Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Drugs", Volume 10 Issue 10, October 2021, International Journal of Science and Research (IJSR), Pages: 36-42, https://www.ijsr.net/getabstract.php?paperid=SR21930175626, DOI: https://dx.doi.org/10.21275/SR21930175626